Evaluation of Anti-Alzheimer Activity of Synthetic Coumarins by Combination of in Vitro and in Silico Approaches

Ilkay Erdogan Orhan, F. Sezer Senol Deniz, Ramin Ekhteiari Salmas, Sule Irmak, Ozden Ozgun Acar, Gurbet Celik Turgut, Alaattin Sen, Ana Maria Zbancioc, Simon Vlad Luca, Adrianna Skiba, Krystyna Skalicka-Woźniak, Gabriela Tataringa

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Series of synthetic coumarin derivatives (1-16) were tested against acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), two enzymes linked to the pathology of Alzheimer's disease (AD). Compound 16 was the most active AChE inhibitor with IC50 32.23±2.91 μM, while the reference (galantamine) had IC50=1.85±0.12 μM. Compounds 9 (IC5075.14±1.82 μM), 13 (IC50=16.14±0.43 μM), were determined to be stronger BChE inhibitors than the reference galantamine (IC50=93.53±2.23 μM). The IC50 value of compound 16 for BChE inhibition (IC50=126.56±11.96 μM) was slightly higher than galantamine. The atomic interactions between the ligands and the key amino acids inside the binding cavities were simulated to determine their ligand-binding positions and free energies. The three inhibitory coumarins (9, 13, 16) were next tested for their effects on the genes associated with AD using human neuroblastoma (SH-SY5Y) cell lines. Our data indicate that they could be considered for further evaluation as new anti-Alzheimer drug candidates.

Original languageEnglish
Article numbere202200315
JournalChemistry and Biodiversity
Issue number12
StatePublished - Dec 2022


  • Alzheimer's disease
  • biological activity
  • cholinesterase inhibition
  • coumarin
  • molecular modeling
  • SH-SY5Y
  • synthetic methods


Dive into the research topics of 'Evaluation of Anti-Alzheimer Activity of Synthetic Coumarins by Combination of in Vitro and in Silico Approaches'. Together they form a unique fingerprint.

Cite this